drugset / Trial / NCT01817855

To Assess the Safety, Tolerability, and Pharmacokinetics of AZD7624 in Healthy Volunteers and COPD Patients

NCT01817855 ↗

Phase 1 Completed 52 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindBasic science

Summary

This study will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of AZD7624 in healthy subjects and patients with chronic obstructive pulmonary disease.

Timeline

Start
2013-09
Primary completion
2014-10
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD7624 Small molecule 300 ug Inhaled
Subject AZD7624 Small molecule 1200 ug Inhaled